Ambit Biosciences is a biotechnology company focused on the discovery and development of novel, targeted small molecule kinase inhibitors to improve outcomes for patients living with cancer. Ambit has adopted an accelerated approach to kinase drug discovery that over the past five years has generated a robust pipeline of targeted oncology therapeutics. Ambit’s lead product candidate, AC220, is a potent, highly selective, oral second-generation FLT3 kinase that is currently in a Phase 2 pivotal study in patients with relapsed / refractory AML, and is part of a worldwide agreement with Astellas Pharma Inc to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 06/01/11 | Series D | 30M | Unknown |
People
Alan Fuhrman (CFO)
Allan Marchington (Board member)
Faheem Hasnain (Board Member)
Wendell Wierenga (EVP, Research & Development)
Alan Lewis (CEO, President)
News
How Indians defied gravity and achieved success in Silicon Valley
October 15, 2012 5:32 pm
If you visited Silicon Valley in the ’50s and ’60s, the only Indians you would meet would be a few… Continue reading ⟩
Nicola Campbell, a 37-year old remarkable VC, passes away
June 10, 2008 5:59 pm
Nicola Campbell, venture capitalist with Sofinnova Ventures, who impressed me deeply with her ambition and intellect over the years I… Continue reading ⟩
VC funding up, biotech outpaces other industries
January 19, 2008 5:00 am
Venture-capital funding continued to rise in the fourth quarter, continuing a recent boom despite economic jitters sown by the subprime-mortgage… Continue reading ⟩